Kakar Maria, Ullah Sami, Khan Amjad, Nazir Shabnam
Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.
Department of Pharmacy, Kohat University of Science and Technology (KUST), Kohat, Pakistan.
PLoS One. 2025 Jan 2;20(1):e0315435. doi: 10.1371/journal.pone.0315435. eCollection 2025.
The use of granulocyte colony-stimulating factor (GCSF) to control febrile neutropenia (FN) caused by anti-cancer chemotherapy is well documented but it still needs to evaluated with respect to the specific type of cancer and chemotherapeutic agents. The present study evaluates the efficacy of adjunctive GCSF for treating FN after taking anticancer therapy by measuring clinical, hematological and microbiological outcomes. It is a single center study conducted at Hayatabad Medical Complex (HMC), Peshawar, Pakistan. Adult patients of both genders, suffering from different types of sarcomas and taking anticancer chemotherapy were included in the study. The study was conducted between January 2023 and January 2024. Baseline data including demographic data, medication history and hematological evaluation of all the patients was recorded at the time of enrolment. Primary outcomes of the study were the extent of absolute neutrophil count (ANC) recovery, duration and severity of neutropenia (grade IV), period to fever resolution. After the therapy (with and without adjunctive GCSF) clinical outcomes, hematological evaluation and microbiological data was compared and evaluated. All the data was statistically analyzed by SPSS (IBMS, version 20). A total number of 120 patients were investigated out of which data of 109 patients was included. Out of 109 patients, 64 (58.72%) received adjunctive GCSF therapy, and 45 (41.28%) did not receive adjunctive GCSF. Comparison of the data showed that the patients receiving adjunctive GCSF had a significant improvement ANC recovery time, better recovery of fever and patients were free of infections. This study concluded that adjunctive GCSF therapy benefits the patients undergoing anticancer treatment for different types of carcinoma.
使用粒细胞集落刺激因子（GCSF）来控制抗癌化疗引起的发热性中性粒细胞减少症（FN）已有充分记录，但仍需针对特定类型的癌症和化疗药物进行评估。本研究通过测量临床、血液学和微生物学结果，评估辅助性GCSF在接受抗癌治疗后治疗FN的疗效。这是一项在巴基斯坦白沙瓦哈亚塔巴德医疗中心（HMC）进行的单中心研究。纳入了患有不同类型肉瘤且正在接受抗癌化疗的成年男女患者。该研究于2023年1月至2024年1月进行。在入组时记录了所有患者的基线数据，包括人口统计学数据、用药史和血液学评估。该研究的主要结果是绝对中性粒细胞计数（ANC）恢复的程度、中性粒细胞减少症（IV级）的持续时间和严重程度、发热消退的时间。在治疗后（使用和不使用辅助性GCSF），对临床结果、血液学评估和微生物学数据进行了比较和评估。所有数据均使用SPSS（IBMS，版本20）进行统计分析。共调查了120名患者，其中纳入了109名患者的数据。在109名患者中，64名（58.72%）接受了辅助性GCSF治疗，45名（41.28%）未接受辅助性GCSF治疗。数据比较显示，接受辅助性GCSF治疗的患者ANC恢复时间有显著改善，发热恢复情况更好，且患者没有感染。本研究得出结论，辅助性GCSF治疗对接受不同类型癌症抗癌治疗的患者有益。
